Here we go again: COVID-19 hospital admissions have inched upward in the United States since early July in a small-scale echo of the three previous summers.
With an updated vaccine still months away, this summer bump in new hospitalizations might be concerning, but the number of patients is far lower than before. A look at what we know:
HOW BAD IS THE SPIKE?
For the week ending July 29, COVID-19 hospital admissions were at 9,056. That's an increase of about 12% from the previous week.
But it's a far cry from past peaks, like the 44,000 weekly hospital admissions in early January, the nearly 45,000 in late July 2022, or the 150,000 admissions during the omicron surge of January 2022.
“It is ticking up a little bit, but it’s not something that we need to raise any alarm bells over,” said Dr. David Dowdy, an infectious disease epidemiologist at Johns Hopkins Bloomberg School of Public Health.
It’s likely that infections are rising too, but the data is scant. Federal authorities ended the public health emergency in May, so the Centers for Disease Control and Prevention and many states no longer track the number of positive test results.
WHAT ABOUT DEATHS?
Since early June, about 500 to 600 people have died each week. The number of deaths appears to be stable this summer, although past increases in deaths have lagged behind hospitalizations.
HOW ARE WE TRACKING THE VIRUS?
The amount of the COVID-19 virus in sewage water has been rising since late June across the nation. In the coming weeks, health officials say they'll keep a close eye on wastewater levels as people return from summer travel and students go back to school.
Higher levels of COVID-19 in wastewater concentrations are being found in the Northeast and South, said Cristin Young, an epidemiologist at Biobot Analytics, the CDC's wastewater surveillance contractor.
“It’s important to remember right now the concentrations are still fairly low,” Young said, adding it's about 2.5 times lower than last summer.
“There are a couple that we’re watching, but we’re not seeing anything like delta or omicron,” Young said, referencing variants that fueled previous surges.
And mutations in the virus don't necessarily make it more dangerous.
“Just because we have a new subvariant doesn’t mean that we are destined to have an increase in bad outcomes," Dowdy said.
WHEN IS THE NEW VACCINE COMING?
This fall, officials expect to see updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5. It’s an important change from today’s combination shots, which mix the original coronavirus strain with last year’s most common omicron variants.
It's not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot. Pfizer, Moderna and smaller manufacturer Novavax all are brewing doses of the XBB update but the Food and Drug Administration will have to sign off on each, and the CDC must then issue recommendations for their use.
Dr. Mandy Cohen, the new CDC director, said she expects people will get their COVID-19 shots where they get their flu shots — at pharmacies and at work — rather than at dedicated locations that were set up early in the pandemic as part of the emergency response.
“This is going to be our first fall and winter season coming out of the public health emergency, and I think we are all recognizing that we are living with COVID, flu, and RSV," Cohen told The Associated Press last week. “But the good news is we have more tools than ever before.”
AP Medical Writers Lauran Neergaard and Mike Stobbe contributed to this report.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
As gas prices surge amid the Russian invasion of Ukraine, other nations could potentially transition faster to using clean energy than previously expected. Philip K. Verleger, a senior fellow at the Niskanen Center, joined Cheddar News to explain how this could be a possibility in the near future. "Part of the reason I think we have this invasion and the tantrum that's being thrown by Russia, terrible tantrum, is because the Russians were trying to slow down the transition," he said. "Ironically they speeded it up."
As Russia intensifies its war on Ukraine, President Biden announced a ban on oil imported from the aggressor nation. Critics of Russia have said this would be the best way to force Putin to pull back, but curbs on Russian oil exports are expected to send already skyrocketing oil and gas prices even higher, further impacting consumers, businesses, financial markets, and the global economy. Leslie Beyer, CEO of the Energy Workforce and Technology Council, joined Cheddar News' Closing Bell to discuss. "It's certainly going to increase pricing, but it is the right thing to do," she said. "The industry itself has already pulled out of the significant portion of its operations in Russia."
On this episode of Cheddar Innovates: Vision Marine Technologies CEO discusses how e-boats will play a role in the fight against the climate crisis; Lasso CEO breaks down how the design behind these compression socks can prevent injuries and improve performance; Cheddar gets a look at Curiosity Stream's 'The Tombs Of Egypt.'
Vaccine maker Pfizer delayed its COVID shot for kids allegedly due to a lack of data on how it would perform against the omnicron variant, according to the Wall Street Journa. Peter Pitts, professor and founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner, joined Cheddar News Wrap to break down why the authorization can't be rushed. "Going forward, the FDA wants to look at data specifically against omicron, and it looks like that's going to be a three-shot regimen versus two, which was efficient against delta but not omicron because obviously omicron is more infectious," said Pitts.
Walker Ross, Assistant Professor of Sports Business Management at Florida Southern College, joins Business of Sports: The Beijing Winter Olympics 2022, where he says that actions Beijing and other Olympic host sites have been implementing to combat climate change has simply not been enough to offset their carbon footprint.
Bamboo-based toilet paper company Cloud Paper raised $5 million in a recent funding round. Its product is a bamboo-based alternative to traditional toilet paper made from trees, and its mission is to end the deforestation caused by traditional paper products. Cloud Paper says the raise will allow it to make significant investments in its supply chain, product development, and hiring. Ryan Fritsch, a co-founder of Cloud Paper, joined Cheddar News' Closing Bell to discuss.
Space tourism company World View plans to launch its first commercial flights in early 2024, with voyages to take off from iconic locations around the world like the Grand Canyon — but seemingly at a flexible price point. Dale Hipsh, president of tourism and exploration at World View, joined Cheddar to discuss what a trip to the stratosphere would look like with his company and its much less expensive take on space travel. "Our technology allows us to be more democratic, to offer more opportunities for people to experience near space, and that overview effect," he said. "So we're really thrilled to be bringing it to market."
A recent NOAA report found America's coastline could experience a century's worth of sea rise in just 30 years. By 2050, water on the U.S. coast will be 10-12 inches higher, causing major eastern cities to be hit regularly with floods, even on sunny days. Gary Mitchum, professor of physical oceanography at the University of South Florida, joins Cheddar News to discuss.
The Biden administration is launching a new task force to promote the use of 'cleaner' construction materials with lower life cycle emissions. This comes as the White House works to speed up government purchases of greener products. Sweta Chakraborty, climate change expert and U.S. president of "We Don't Have Time," joins Cheddar News to discuss.
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
